|Day Low/High||19.11 / 19.78|
|52 Wk Low/High||16.63 / 32.23|
Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day.
Allergan (AGN) was the best performer on the S&P 500 Monday after Teva Pharmaceuticals (TEVA) agreed to buy its generic-drug business for more than $40 billion.
Pharmaceutical firm's chart shows a likely move to the upside.
Deal flow has been massive in the first half of 2015 from healthcare to technology to insurance.
Sector may not be as bulletproof as we thought.
Jim Cramer answers your Twitter questions about FireEye (FEYE) and other stocks from the floor of the New York Stock Exchange.
Deals coming fast and furious in the best group in town.
The Merger Fund seeks absolute returns and is not correlated to the stock market so it will fare well in a rising rate environment.
The surge in deal-making has created the ideal environment for merger arbitrage or event-driven funds, said K.C. Nelson, portfolio manager for the Driehaus Event Driven Fund.
Stock losses escalated in the closing minutes of Monday's session.
The Nasdaq was the clear winner on markets Friday. The tech-heavy index spiked into record territory as Amazon (AMZN), Microsoft (MSFT) and Google (GOOGL) rallied after reporting earnings.
Recent activity has heated up and is creating shareholder value.
Here are healthcare stocks of all shares and sizes with strong charts.
Whether it's acquiring or the acquired, Mylan is building shareholder value.